- Home
- ZNTL vs ZH Comparison
ZNTL vs ZH Comparison
Compare ZNTL & ZH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZNTL
- ZH
- Stock Information
- Founded
- ZNTL 2014
- ZH 2011
- Country
- ZNTL United States
- ZH China
- Employees
- ZNTL N/A
- ZH N/A
- Industry
- ZNTL Biotechnology: Pharmaceutical Preparations
- ZH Business Services
- Sector
- ZNTL Health Care
- ZH Consumer Discretionary
- Exchange
- ZNTL Nasdaq
- ZH Nasdaq
- Market Cap
- ZNTL 238.2M
- ZH 387.2M
- IPO Year
- ZNTL 2020
- ZH 2021
- Fundamental
- Price
- ZNTL $3.12
- ZH $3.58
- Analyst Decision
- ZNTL Buy
- ZH Strong Buy
- Analyst Count
- ZNTL 7
- ZH 2
- Target Price
- ZNTL $10.86
- ZH $6.00
- AVG Volume (30 Days)
- ZNTL 1.2M
- ZH 798.2K
- Earning Date
- ZNTL 11-04-2024
- ZH 11-27-2024
- Dividend Yield
- ZNTL N/A
- ZH N/A
- EPS Growth
- ZNTL N/A
- ZH N/A
- EPS
- ZNTL N/A
- ZH N/A
- Revenue
- ZNTL $40,560,000.00
- ZH $558,027,906.00
- Revenue This Year
- ZNTL N/A
- ZH N/A
- Revenue Next Year
- ZNTL N/A
- ZH $7.55
- P/E Ratio
- ZNTL N/A
- ZH N/A
- Revenue Growth
- ZNTL N/A
- ZH N/A
- 52 Week Low
- ZNTL $2.83
- ZH $2.55
- 52 Week High
- ZNTL $18.24
- ZH $6.36
- Technical
- Relative Strength Index (RSI)
- ZNTL 44.34
- ZH 46.23
- Support Level
- ZNTL $2.92
- ZH $3.56
- Resistance Level
- ZNTL $3.23
- ZH $3.71
- Average True Range (ATR)
- ZNTL 0.17
- ZH 0.23
- MACD
- ZNTL 0.00
- ZH -0.08
- Stochastic Oscillator
- ZNTL 38.33
- ZH 12.50
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.
About ZH Zhihu Inc. (every two of each representing one ordinary share)
Zhihu Inc is predominantly engaged in the operation of one online content community and monetizes through paid membership services, advertising services, content-commerce solutions services, and vocational training in China. It generates revenues from Advertising services, Paid membership services, Content-commerce solutions, and Others. It derives all its revenues within China.